The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
myHomecare Group
Advising Australian Unity on its acquisition of myHomecare Group
Liontown Resources Limited
Advised Australian-based lithium company Liontown Resources Limited on its A$855m debt financing package and up to A$421m equity raising to fund the Kathleen Valley Lithium Project
Liontown Resources Limited
Advising Australian-based lithium company Liontown Resources Limited on its response to change of control proposals from Albemarle Corporation
Farmalider Group
Advising the shareholders of Grupo Farmalider, a B2B Spanish pharmaceutical company focused on contract manufacturing, innovation and development of products based on generics, on the sale of an undisclosed stake to local private equity MCH
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
Clinigen Ltd’s Lamda Laboratories
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
Kyowa Kirin International’s established medicines business
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
OZ Minerals Limited
Advising Australian-based copper company OZ Minerals Limited, on its response to two change of control proposals from BHP Group Limited, the world’s largest diversified resources company
Liontown Resources
Advised Liontown Resources, an ASX-listed lithium company focused on the development of the world-class Kathleen Valley Lithium Project, on a lithium spodumene concentrate offtake agreement and A$300m financing facility from Ford Motor Company
Syrah Resources
Advisor to Syrah Resources, an ASX-listed industrial minerals and technology company, on its US$107mm loan from the U.S. Department of Energy under the Advanced Technology Vehicles Manufacturing loan program to fund the initial expansion of its Vidalia active anode material facility in Louisiana, USA
DGO Gold
Advising DGO Gold, an ASX-listed gold exploration company, on its recommended, off-market takeover offer from Gold Road Resources, an ASX-listed gold producer
Acacia Pharma Group plc
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
Liontown Resources
Advised Liontown Resources, an ASX-listed lithium company focused on the development of the world class Kathleen Valley Lithium Project, on a lithium spodumene concentrate offtake agreement with Tesla, a major electric vehicle manufacturer
Akorn Pharmaceuticals Portfolio of Branded Ophthalmic Products
Advised Akorn Pharmaceuticals, a specialty pharmaceuticals manufacturer and marketer, on the divestiture of its portfolio of branded ophthalmic products to Laboratoires Théa SAS
Liontown Resources
Advised Liontown Resources, an ASX-listed lithium company focused on the development of the world class Kathleen Valley Lithium Project, on a lithium spodumene concentrate offtake agreement with LG Energy Solutions, a major South Korean-based EV battery supplier for leading global automakers
Syrah Resources
Advised Syrah Resources, an ASX-listed industrial minerals and technology company, on a natural graphite active anode material offtake agreement with Tesla, the world’s largest EV manufacturer
Liontown Resources
Advised Liontown Resources, an ASX-listed lithium company focused on the development of the world class Kathleen Valley Lithium Project, on its A$490m equity raising, comprised of a fully underwritten placement of A$450m and a non-underwritten share purchase plan of A$40m
MetalX, Inc.
Advised MetalX, Inc., a leading ferrous and non-ferrous metal scrap recycling company, on the sale of substantially all of its ferrous scrap processing business to BlueScope Steel Limited, an Australian-listed provider of steel materials, products, systems and technologies
Metro Quarry Group
Advised Myer Family Investments on the sale of the assets of Metro Quarry Group (Victoria’s largest specialist sand quarry) to a joint venture comprising Adbri / Barro Group
Faes Farma, flagship product Bilastine
Advised Faes Farma in the signing of a long-term license agreement for its flagship product Bilastine with Hikma Specialty USA INC, a subsidiary of Hikma Pharmaceuticals PLC, for the United States of America
Deltalab
Advising Deltalab, a leading Spanish laboratory solutions provider with dedicated manufacturing capacity, on the sale of the company to SCG Packaging Public Company Limited, the largest integrated packaging and paper company in Southeast Asia
Portfolio of 16 European Consumer Healthcare brands from Sanofi
Advising Sanofi, a leading global player in the Consumer Healthcare market, on the divestiture of a portfolio of 16 European Consumer Healthcare brands to STADA, a German pharmaceutical and consumer healthcare company owned by Bain Capital and Cinven
Acacia Pharma Group plc
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
Alumisource Corporation
Advised Sims Limited, a global leader in metal recycling and electronics recovery, on the acquisition of certain commercial and operating assets of Alumisource Corporation
Cosmetic applications endolysin
Advised Micreos, a fast-growing biotechnology company, on a long-term license agreement with L’Oréal for one of Micreos’ phage-based active ingredients, SA.100
Centrifuge and processing equipment business of Koki Holdings Co., Ltd.
Advised Eppendorf AG, a leading family-owned life science company, on the acquisition of the centrifuge and processing equipment business of KKR-owned Koki Holdings Co., Ltd., a manufacturer of power tools and centrifuge and processing equipment
Formation of an incorporated joint venture
Advised Flinders Mines, an ASX-listed mining exploration and development company, on the formation of an incorporated joint venture with BBI Group, providing a structure for the potential integrated financing and development of Flinders’ Pilbara Iron Ore Project and BBI Group’s Balla Balla rail and port infrastructure project
Global rights (excluding North America) to ThermaCare (United Kingdom)
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma
Kidman Resources Limited
Advised Kidman Resources, an ASX-listed hard rock lithium mining company, on its sale to Wesfarmers, one of Australia’s largest diversified listed companies
Starpharma Holdings Limited, patented VivaGel BV® product
Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company
Long-term lithium hydroxide offtake agreement with Mitsui & Co.
Advised Kidman Resources Limited, an ASX-listed hard rock lithium mining company with a 50% interest in the West Australian Mt. Holland lithium project, on a lithium hydroxide offtake agreement with Mitsui & Co., a leading global marketing and trading conglomerate based in Japan. The agreement is for an initial term of two years, plus two 2-year term extension options
US$115mm Debt Facility from SQM
Advised Kidman Resources Limited, an ASX-listed hard rock lithium mining company with a 50% interest in the West Australian Mt. Holland lithium project, on a US$115mm debt facility provided by JV partner Sociedad Quimica y Minera de Chile S.A. (SQM), a leading global lithium producer
Montserrat Day Hospital Group
Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities
Martabe gold and silver mine
Advised EMR Capital, a specialist resources private equity manager, on the sale of the Martabe gold and silver mine to United Tractors
Long-term lithium hydroxide offtake agreement with Tesla, Inc.
Advised Kidman Resources Limited, an ASX-listed hard rock lithium mining company with a 50% interest in the West Australian Mt. Holland lithium project, on a lithium hydroxide offtake agreement with Tesla, Inc., a global leader in electric vehicle, energy storage and solar panel design, development and manufacturing. The agreement is for an initial term of three years on a fixed-price take-or-pay basis and contains two 3-year term renewal options
Novartis AG’s 36.5% stake in Consumer Health Joint Venture
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture
MorphoSys AG
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
Hirslanden Private Hospital Group
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
Bionomics Limited
Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.
US rights to 37 approved and 5 pipeline generic products
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
Boehringer Ingelheim
Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.
Allied Healthcare
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
Refinancing of syndicated bank debt facilities
Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities
TITAL GmbH
Advised Alcoa Inc. on the acquisition of TITAL GmbH, a privately-held German manufacturer of aluminum and titanium castings predominately for the aerospace and defense end markets
Boart Longyear Ltd.
Advised the Board of Directors of Boart Longyear, the world’s leading supplier of drilling services and equipment for mining and drilling companies, on its strategic review process and subsequent comprehensive recapitalization transactions with certain affiliates of Centerbridge Partners, L.P.
MannKind Corporation
Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.
Siemens Health Services
Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.
Clinuvel Pharmaceuticals Limited
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
Forest Laboratories Inc.
Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.
Warner Chilcott, plc
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
Mediclinic International Limited
Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa
iNova Pharmaceuticals
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
Coal and Allied Industries Limited
Advised Coal and Allied Industries Limited, an Australian based coal mining company, in relation to an acquisition proposal from Rio Tinto Limited and Mitsubishi Corporation to acquire all the outstanding shares in the company not already held by Rio Tinto and Mitsubishi
Territory Resources Limited
Advised Exxaro Resources, a diversified South African-based mining company, on its proposed acquisition of Territory Resources, an Australian-based iron producer
Bionomics Ltd
Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics
Alcon, Inc.
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
Healthcare Australia
Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK
Lihir Gold Limited
Advised Lihir Gold Limited, a leading global gold company with operations in Papua New Guinea, Australian and West Africa on an unsolicited takeover proposal from Newcrest Mining Ltd, an international gold company with gold and copper operations
Enzon Pharmaceuticals, Inc.
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
Genentech, Inc.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
Biotage (Biosystems division)
Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research
Lonmin plc
Advised Lonmin plc, a major producer of Platinum Group Metals, regarding an unsolicited pre-conditional offer for the company by Xstrata plc, a global diversified mining company
Ventana Medical Systems, Inc.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment
Schering AG
Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany